ADTX Aditxt, Inc.

Nasdaq Pharmaceutical Preparations DE CIK: 0001726711
AI RATING
STRONG_SELL
98% Confidence

Investment Thesis

Aditxt faces imminent financial distress with negative stockholders equity of -$33.3M, liabilities exceeding assets by $35.2M, and critically depleted cash reserves of $268.9K supporting -$4.6M annual operating cash burn. Revenue has collapsed 97.6% YoY to $12.2K with no evidence of operational recovery, leaving the company technically insolvent with an estimated 2-3 months of cash runway at current burn rates.

Strengths

  • + Positive gross margin of 23.6% on products suggests underlying unit economics may exist if revenue can be restored
  • + Total assets of $13.9M provide some liquidation value
  • + Moderate insider activity (2 Form 4 filings in 90 days) suggests limited insider panic selling

Risks

  • ! Negative stockholders equity of -$33.3M indicates technical insolvency and company is balance-sheet underwater
  • ! Severe liquidity crisis with 0.06x current ratio and only $268.9K cash against operating cash burn of -$4.6M annually
  • ! Revenue collapse of 97.6% YoY to $12.2K indicates loss of core business operations with no visible path to recovery
  • ! Liabilities exceed assets by $35.2M requiring significant debt restructuring, dilution, or bankruptcy proceeding
  • ! Estimated 2-3 months of cash runway suggests high probability of financing distress, default, or bankruptcy filing
  • ! Long-term debt of $3.1M at risk given negative cash flows and insolvency status

Key Metrics to Watch

Financial Metrics

Revenue
12.2K
Net Income
-15.9M
EPS (Diluted)
$-790.49
Free Cash Flow
-4.6M
Total Assets
13.9M
Cash
268.9K

Profitability Ratios

Gross Margin 23.6%
Operating Margin -35,873.5%
Net Margin -131,159.8%
ROE N/A
ROA -114.7%
FCF Margin -37,742.3%

Balance Sheet & Liquidity

Current Ratio
0.06x
Quick Ratio
0.05x
Debt/Equity
N/A
Debt/Assets
352.9%
Interest Coverage
N/A
Long-term Debt
3.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: 2026-05-23T07:34:07.512986 | Data as of: 2026-03-31 | Powered by Claude AI